

Review of: "[Review Article] Pitavastatin: A Comprehensive Overview of its Mechanisms, Pharmacokinetics, Pharmacodynamics, and Adverse Effects"

Nicolas Roberto Robles

Potential competing interests: No potential competing interests to declare.

The manuscript has a lot of pitfalls.

1. Introduction: "It is used to raise HDL-cholesterol," "to enhance high-density lipoproteins and decrease increased levels of triglycerides." The effect of statins on HDL-cholesterol is small, even for pitavastatin, and they are not usually used for this target.

2. "It was first made accessible in Japan in 2003, and it is currently being sold in South Korea and India under permission [9]," and also all over Europe.

3. "...minimize cardiovascular morbidity and mortality in both people with and without coronary heart disease (CHD) [12]." The reference does not support the opinion.

4. "Pitavastatin, the only lipid-lowering research with statins, has shown a correlation between drug-induced increases in HDL-C and decreased cardiovascular risk [42]." Again, the reference does not support this sentence.

5. Discussion. "Additionally, pitavastatin had no effect on fasting glucose levels [50]." There are a lot of important references about pitavastatin that have not been included. The best effect of pitavastatin is to avoid diabetes mellitus induced by statins. Even more, it reduces FPG.

6. Conclusions: Untidy and do not relate to the text.